Genentech’s Xolair Receives FDA’s Breakthrough Therapy Designation for Food Allergies
Genentech Collaborates with Immunocore to Co-develop IMC-C103C for MAGE-A4 (Melanoma-Associated Antigen A4)
Shots:
- The BT designation is based on seven clinical studies evaluating safety and efficacy for allergens including peanut, milk, egg and others
- The BT designation for Xolair (omalizumab) is to prevent severe allergic reactions following accidental exposure to one or more foods in people with allergies
- Genentech and Novartis are working with NIAID and the Consortium of Food Allergy Research (CoFAR) initiating a pivotal study for evaluating the efficacy and safety of Xolair in multiple food allergies. Additionally, Genentech and Novartis are working to co-develop and co-promote Xolair
Click here to read full press release/ article | Ref: Roche | Image: Forbes